Mood Enhancing Supplement Market Size, Share, Growth and Forecast, 2025-2035

Stress, low mood and ingredient rules shape buyer demand

The global mood enhancing supplement market was valued at USD 5.38 billion in 2025 and is projected to increase from USD 5.78 billion in 2026 to USD 10.99 billion by 2035, registering a CAGR of 7.40% during 2026–2035. Demand comes from adults who manage stress, low mood and poor sleep with nonprescription products, and from retailers that give calming gummies, magnesium and botanical capsules more shelf space. North America held the largest regional share, 38.0% in 2025, because supplement use is habitual among U.S. adults and mass retailers carry broad stress and mood ranges. Asia Pacific is the fastest-growing region at 8.4% a year, helped by Japan's functional claims system and China's separate cross-border e-commerce route for imports. Regulation is the main commercial change, because reviews of ashwagandha in Europe and India and stricter Chinese import documentation from June 2026 push brands toward root-only extracts, clinically studied branded ingredients and amino acids such as GABA and L-theanine.

Which products and ingredients make up mood support spending?

The market covers capsules, tablets, gummies, powders and drinks sold as dietary or food supplements with mood, stress or emotional well-being positioning. Typical actives are ashwagandha, rhodiola, saffron and lemon balm, magnesium and B vitamins, and amino acids such as GABA, L-theanine and 5-HTP. Value is measured at manufacturer selling prices across pharmacies, mass retail, specialty stores and online channels.

Prescription antidepressants and anxiolytics are excluded, as are conventional foods without supplement status. The value chain runs from botanical growers and extract makers through branded ingredient suppliers and contract manufacturers to consumer brands, which hold most of the margin through shelf placement and marketing.

Botanicals lead while amino acid formulas grow fastest

Botanicals hold the lead as amino acids gain

Based on product type, the market is categorized into herbal and botanical supplements, vitamins and minerals, and amino acids and nootropics. Herbal & Botanical Supplements led with 42.0% of 2025 value because ashwagandha, saffron and lemon balm anchor most stress formulas, and the Council for Responsible Nutrition's 2024 survey found ashwagandha use at 8% of U.S. supplement users, up from 2% in 2020. Amino Acids & Nootropics grow fastest at 8.3% a year as GABA and L-theanine gain from botanical caution, and Japan counted GABA in 250 functional claim products in fiscal 2023, according to NutraIngredients. Amino acid lines also face fewer safety reviews than most herbal ingredients.

Stores launch products while online channels gain repeat orders

Based on distribution channel, the market is categorized into offline channels and online channels. Offline Channels led with 53.0% of 2025 value because pharmacy and mass retail still launch most mood ranges, and Nature's Bounty placed its Stress Comfort gummies at CVS, Walgreens, Walmart and Kroger, according to Drug Store News. Online Channels grow fastest at 8.0% a year as marketplace sellers chase trending ingredients, and Modern Retail reported in February 2026 that one e-commerce platform saw a 500% rise in stores selling magnesium products within six months. Stores win the first purchase, while repeat orders move online.

Working-age adults buy most while younger buyers grow fastest

Based on end user, the market is categorized into adults, the geriatric population and teenagers and young adults. Adults led with 62.0% of 2025 value because working-age adults buy most stress and sleep formulas, and the CDC measured depression in 16.6% of U.S. adults aged 20 to 39 during August 2021 to August 2023. Teenagers & Young Adults grow fastest at 8.3% a year as prevalence is highest among the young, with the same CDC survey finding 19.2% among those aged 12 to 19. Brands design gummies and drinks for younger buyers, while older buyers favor magnesium and B vitamins.

Shelf prices cluster near USD 0.60 a day for mass formulas

Mood products are priced per pack, but buyers compare cost per day, which sits near USD 0.60 for mass-market gummies. A 42-count OLLY pack covers 21 days at about USD 12.50, and a 60-capsule KSM-66 ashwagandha bottle at USD 23.99 lasts 30 to 60 days depending on dose. Branded, trial-backed extracts command the largest premiums because retailers and practitioners accept their claims, while generic herbs compete on price in marketplaces. Ingredient costs, safety testing and retail placement fees move shelf prices the most. Brands that can point to a published trial keep their margins, while private label pulls down prices for magnesium and single herbs.

Depression rates and daily supplement habits lift sales

Higher depression and anxiety rates widen the buyer pool

Mental health strain enlarges the group of people looking for nonprescription mood support. The World Health Organization said on Sept. 2, 2025, that more than 1 billion people live with mental health conditions, with anxiety and depression the most common, costing the global economy about USD 1 trillion a year. In the United States, depression prevalence rose to 13.1% in August 2021 to August 2023 from 8.2% in 2013 to 2014, and only 39.3% of those affected received counseling in the past year. This treatment gap leaves many adults to self-manage mild symptoms. It favors products sold next to sleep and stress aids in pharmacies, where first-time buyers browse and compare labels before they commit to a daily routine.

Daily supplement habits make mood formulas an easy add-on

Mood products sell most easily to consumers who already take supplements every day. The Council for Responsible Nutrition reported on Oct. 29, 2024, that about 75% of Americans use dietary supplements, a share unchanged from the previous year, and magnesium use rose to 23% of users from 19% in 2023. Melatonin reached 16% of users, up from 10% in 2020, which shows how quickly calming and sleep products can scale once shoppers adopt them. Solaray told Modern Retail in February 2026 that magnesium demand had required triple shifts at its magnesium operations since late 2023. Brands therefore build mood lines as extensions of trusted mineral and sleep ranges rather than as stand-alone launches, which lowers the cost of winning a new buyer.

Download Free Sample

Clinical trials give branded extracts a pricing argument

Published human trials let ingredient suppliers and brands charge more than commodity herbs and defend claims with retailers. Pharmactive reported on June 24, 2025, that a 12-week randomized trial of its affron saffron extract in 202 adults with subclinical low mood, published in the Journal of Nutrition, found improvement in 72% of the saffron group against 54% on placebo at 28 mg a day. Nutrition21 launched EverZen on March 26, 2025, a 6-MBOA plant bioactive positioned as an alternative to ashwagandha for capsules, gummies and powders. Ethical Naturals' AlphaWave L-theanine has been tested in three clinical studies, according to NutraIngredients. Evidence also shortens retailer reviews, so trial-backed ingredients reach shelves faster than unstudied blends.

Thin public mental health spending pushes self-care

Thin public spending on mental health pushes many consumers toward self-care, particularly outside high-income markets. The World Health Organization found in its September 2025 reports that governments spend a median 2% of health budgets on mental health, unchanged since 2017, with spending as low as USD 0.04 per person in low-income countries against up to USD 65 in high-income countries. Distributors are building pharmacy and app-based retail routes to reach these buyers. NutraONE signed a partnership at World Health Expo in Dubai on Feb. 11, 2026, planning more than 100 SKUs, including brain and nervous system support, for the UAE, Saudi Arabia and other markets, according to Khaleej Times. Pharmacy chains and delivery apps carry the products, which lets imported brands enter without their own stores.

Blends and root-only sourcing replace single-herb formulas

Shift from single herbs to magnesium and amino acid blends

Buyers are moving away from single-herb products toward combinations built on minerals and amino acids. NutraIngredients reported in September 2024 that U.S. retail sales of ashwagandha stress products fell 16% to just over USD 72 million in the 52 weeks to July 14, 2024, while magnesium rose 13.8%, L-theanine 49.8% and kava 125.7%. Solaray launched StressMag, which pairs magnesium glycinate with ashwagandha, according to Modern Retail. OLLY's Goodbye Stress gummies combine 100 mg of GABA, 50 mg of L-theanine and 75 mg of lemon balm per serving. Blends spread ingredient risk, so a safety review of one herb does not remove a whole product from shelves.

Rise of root-only, traceable ashwagandha supply

Ingredient buyers are moving toward root-only, documented ashwagandha as regulators question leaf extracts. India's food regulator issued an advisory on April 16, 2026, against ashwagandha leaves in any form in food products, citing higher withaferin A in leaves, a day after an Ayush directive. Ixoreal Biomed said its root-only KSM-66 supply would not be disrupted, while Kerry said it was appealing. India grows the crop on about 25,000 acres, yielding about 5,000 metric tons of roots. The Karnataka High Court later stayed the advisory for Kerry and other petitioners, according to Deccan Herald. Brands buying root extracts with plant-part labels avoid relabeling if the rule is upheld.

Download Free Sample

Opportunity in mood drinks and functional food formats

Drinks and snacks give brands an opportunity to reach mood buyers who do not take pills. Recess built its Mood line around magnesium L-threonate and became the second-fastest-growing beverage brand on Instacart, Modern Retail reported in February 2026. Solaray linked a mid-2023 spike in magnesium sales to the Sleepy Girl Mocktail social media trend, a drink ritual rather than a pill routine. Japan's functional claims system lets foods as well as supplements carry stress and sleep claims, and GABA appeared in 250 notified products in fiscal 2023. For ingredient makers, functional food ingredients with stable taste and dose open a second channel beside capsules.

Opportunity in amino acid formulas under Brazil's new lists

Brazil's updated ingredient lists open an opportunity for amino acid mood formulas that previously needed a full dossier. Under ANVISA rules, ingredients on the positive lists can be used without extra authorization, and Maven Regulatory Solutions reported in December 2025 that Normative Instruction 373/2025 added GABA, with a transition period running to June 2027. The same update added new probiotic strains, which supports gut-brain positioning. RDC 843/2024 introduced risk-based notification for low-risk products, while registration of novel ingredients takes about 12 to 18 months. Brands that reformulate around listed ingredients can launch through notification, which cuts cost and time against rivals relying on unlisted botanicals.

Herb safety reviews and import rules lift compliance costs

European reviews of ashwagandha threaten herbal ranges

European scrutiny of ashwagandha puts the largest herbal ingredient at risk in the region. Denmark banned the herb in food supplements in 2023, the Dutch institute RIVM advised against its use in spring 2024, and the U.K. Food Standards Agency opened a call for evidence in 2024, according to NutraIngredients. EU regulators were weighing an Article 8 review in 2026. Brands selling across Europe must hold reformulated stock in case of restrictions, a burden that raises inventory costs and slows launches.

Unapproved drugs sold as mood products damage trust

Illegal products sold as mood or focus supplements damage trust in the whole category. The FDA has warned consumers not to buy any tianeptine product, an unapproved compound marketed as a nootropic or supplement, after reports of seizures, loss of consciousness and death, and it updated the alert on May 8, 2025. The agency also wrote to convenience store and gas station trade groups on Jan. 11, 2024, urging them to stop selling such products. Legitimate brands carry the cost of third-party testing and clearer labels to stand apart.

China's import documentation slows key mood ingredients

China's new import rules add paperwork for several mood ingredients and lengthen lead times for exporters. GACC Decree No. 280 took effect on June 1, 2026, and its key regulated ingredients list includes ashwagandha, 5-HTP, tryptophan, magnesium glycinate and melatonin, according to CIRS Group. Products with these ingredients need a certificate of origin, a certificate of free sale and official proof of approved food use. Cross-border e-commerce retail remains under separate personal-use rules, which shifts more volume to that route.

Canadian licensing fees raise the cost of long product ranges

Canada's planned licensing fees make long tails of mood products more expensive to keep on shelf. Health Canada set a revised annual right-to-sell fee of CAD 154 per licensed product in the first year, rising to CAD 317 by the seventh year, plus application fees from CAD 128 for low-risk Class I products. Health Canada has postponed the start from the Dec. 1, 2025, date in its proposal and has not set a new one. Brands with many single-ingredient SKUs will prune ranges, which favors companies with fewer, broader formulas.

North America leads while Asia Pacific grows fastest

North America leads on habitual use and mass retail reach

North America held 38.0% of 2025 value and grows at 6.9% a year. The United States anchors the region because daily supplement use is common among adults and mood products sit inside mass ranges at pharmacies and supercenters, as the survey and shelf data above show. Growth is slower than in Asia Pacific because penetration is already high, so brands compete for switching buyers through new ingredients, formats and price tiers. Canada adds licensing cost, which narrows ranges rather than demand.

Europe grows slowly as claim rules and herb reviews bite

Europe held 26.5% of 2025 value and grows at 6.7% a year. Claims are the main constraint, because about 2,000 botanical health claims have been on hold since 2012, and the European Parliament asked the Commission in February 2024 to resolve them and to create an EU negative list of botanicals, according to Vitafoods Insights. Without approved botanical claims, brands lean on vitamin and mineral formulas and on packaging that avoids direct mood promises, which limits premium pricing.

Download Free Sample

Asia Pacific grows fastest as Japan and China formalize rules

Asia Pacific held 25.0% of 2025 value and is the fastest-growing region at 8.4% a year. Japan's functional claims system gives GABA and similar ingredients a legal route to stress and sleep claims, and after the Kobayashi red yeast rice case the Consumer Affairs Agency required adverse event reporting from Sept. 1, 2024, and GMP for supplement formats from Sept. 1, 2026, according to NutraIngredients. India, which grows most of the world's ashwagandha root, is the main supply base for the herbal group. Stricter rules raise costs but give compliant brands a credibility edge.

Latin America gains from Brazil's clearer ingredient lists

Latin America held 6.0% of 2025 value and grows at 8.0% a year. Brazil is the largest market in the region and sets the pace through the ANVISA positive lists and notification route described above, which lower the cost of launching amino acid and vitamin formulas. Other markets in the region rely more on imported brands sold through pharmacy chains and marketplaces. Currency swings raise shelf prices for imports, so value growth tends to run ahead of volume growth.

Middle East and Africa build demand through pharmacy chains

Middle East & Africa held 4.5% of 2025 value and grows at 8.1% a year. Gulf states lead regional spending, as imported brands reach buyers through pharmacy chains and delivery apps, the distribution model behind the NutraONE partnership noted above. Public mental health spending is thin across much of Africa, which leaves self-care products as the main option for mild symptoms but limits volume to urban, higher-income buyers. Registration with national food and drug authorities remains the main entry cost.

Download Free Sample

Launches, trials and a brand sale marked 2025 and 2026

Low-dose bioactives and gummy formats change product design

• Low-dose bioactives such as the 6-MBOA in EverZen let brands deliver an active ingredient in small capsules, chews and gummies, which frees room in a serving for minerals or vitamins.
• Standardized root extracts carry fixed withanolide levels and documented plant parts, which helps brands meet root-only rules in India and answer safety questions from European regulators.
• Magnesium chelates such as glycinate and L-threonate improve tolerance and carry calm and mood positioning into capsules, powders and ready-to-drink beverages.
• Amino acid stacks combine GABA, L-theanine and other nootropic ingredients for focus and calm in one daily dose, often in gummy form for buyers who dislike capsules.
• Third-party testing programs check identity, purity and dose against the label, helping legitimate brands separate their products from adulterated items sold online.

Mass brands and branded ingredient makers set competition

Competition splits between mass brands that win on shelf reach and price, premium and practitioner brands that win on formulation and trust, and ingredient makers that win on clinical data. Pharmavite, owned by Otsuka, sells Nature Made through U.S. pharmacy and mass retail, where its stress and sleep lines sit beside the category's calming gummies. Nestlé Health Science is narrowing toward Solgar and Pure Encapsulations after agreeing to sell its mainstream brands. Gaia Herbs offers about 20 stress support products and NOW Health Group dozens across stress, sleep and mood, according to NutraIngredients. OLLY and Solaray push gummy formats and magnesium blends into mass and specialty stores. Upstream, Ixoreal Biomed, Sabinsa, Kerry, Pharmactive and Nutrition21 sell branded ingredients to brands. Competition increasingly turns on regulatory readiness, because a ban on one herb can remove a competitor's lead product within months.

How concentrated is the supply side?

The mood enhancing supplement supply side is fragmented at the brand level but more concentrated upstream. A few branded ingredient makers, including Ixoreal Biomed for KSM-66 ashwagandha, Pharmactive for affron saffron and Nutrition21 for EverZen, own the clinical data that brands license. Contract manufacturers produce much of the finished goods, which keeps entry barriers low for new brands but raises them for anyone needing trials or GMP-certified supply. Margins sit with brand owners that control shelf space and with patented ingredient makers, while extract traders and private-label makers earn the least. Large food and pharmaceutical groups are pruning mainstream lines, as the Nestlé sale shows.

Companies profiled and their roles in this market

Clinical proof, not herb fashion, decides share gains

Credence Research's view is that the mood enhancing supplement market will grow through substitution more than through new users. Supplement use is already high in the largest market, so gains go to brands that move buyers from commodity herbs to formulas with trial data and settled regulatory status. Ashwagandha remains the biggest single risk, because restrictions in Europe or India could strip leading herbal products from shelves within months. Suppliers with diversified ingredient portfolios, root-only sourcing and published trials are best placed, while private-label herbal ranges face both price pressure and regulatory exposure.

Health statistics and retail prices anchor the estimate

The report uses 2025 as the base year and forecasts to 2035. Market values come from the Credence Research model, built from public health statistics, consumer survey data published by trade associations, retail price checks, regulatory notices and company announcements. The 2025 value was rebuilt from U.S. mood and stress supplement spending and the U.S. share of global demand, replacing the earlier 2024-based estimate. Regional, product, channel and end-user splits are Credence Research estimates. No interviews or primary surveys were conducted by Credence Research for this edition.

Evidence-backed formulas gain share through 2035

By 2035 the mood enhancing supplement market reaches USD 10.99 billion, with growth tilted toward amino acid and mineral formulas, online channels and younger buyers. Herbal products remain the largest group, but their share narrows as regulators settle the status of ashwagandha and other botanicals. Asia Pacific gains share as Japan's GMP rules and China's import rules mature into stable routes for compliant suppliers. Brands that pair clinical data with simple daily formats such as gummies and drinks will take most of the growth, while generic single-herb ranges lose share to private label and reformulated blends.

Regulation and clinical proof set the range of outcomes

The range of outcomes depends mainly on how regulators treat botanicals and how fast trial-backed ingredients replace generic herbs. In the downside case, an EU restriction on ashwagandha and slower Chinese import clearance cut herbal sales without full replacement by other actives. The base case assumes gradual substitution toward amino acids, minerals and studied extracts. The upside case requires faster positive-list approvals in Brazil and Asia and wider retail acceptance of clinically supported claims.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.